JAK1 and neoplasm: Co-treatment with genistein and the JAK1 pathway inhibitor GLPG0634 (1 mg/kg) or the Akt pathway inhibitor MK-2206 (1 mg/kg) had an enhanced inhibitory effect on tumor growth in comparison with matched control groups (Figure 6I–6L, P<0.01).